The Need for Randomized Clinical Trials Demonstrating Reduction in All-Cause Mortality With Blood Tests for Cancer Screening

JAMA Intern Med. 2023 Oct 1;183(10):1051-1053. doi: 10.1001/jamainternmed.2023.3610.

Authors

Sanket S Dhruva^{1

2}, Rebecca Smith-Bindman^{2

3}, Rita F Redberg^{2

4}

Affiliations

¹ Section of Cardiology, Department of Medicine, San Francisco Veterans Affairs Medical Center, San Francisco, California.
² Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco.
³ Department of Epidemiology and Biostatistics, University of California, San Francisco, School of Medicine.
⁴ Division of Cardiology, Department of Medicine, University of California, San Francisco, School of Medicine.

PMID: 37639263
DOI: 10.1001/jamainternmed.2023.3610

No abstract available

Publication types

Editorial
Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

Colorectal Neoplasms* / diagnosis
Early Detection of Cancer
Hematologic Tests
Humans
Lung Neoplasms* / diagnosis
Mass Screening
Randomized Controlled Trials as Topic